Apellis Pharmaceuticals Inc (APLS)
$37.55
Live
Insights on Apellis Pharmaceuticals Inc
Increasing Revenue
Revenue is up for the last 6 quarters, 14.38M → 89.64M (in $), with an average increase of 27.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -177.77M → -122.03M (in $), with an average increase of 45.7% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 66.6% return, outperforming this stock by 102.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 155.7% return, outperforming this stock by 129.2%
Performance
- $36.97$38.57$37.55
1.56%
Downside
Day's Volatility :4.16%
Upside
2.64%
- $19.83$94.75$37.55
47.19%
Downside
52 Weeks Volatility :79.07%
Upside
60.37%
Returns
| Period | Apellis Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -55.89% | -3.2% | 0.0% |
6 Months | -50.11% | -2.7% | 0.0% |
1 Year | -35.63% | 0.8% | -0.4% |
3 Years | 17.95% | 22.3% | 14.9% |
Highlights
Market Capitalization | 4.5B |
Book Value | $2.94 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -5.59 |
Wall Street Target Price | 67.64 |
Profit Margin | 0.0% |
Operating Margin TTM | -331.93% |
Return On Assets TTM | -39.92% |
Return On Equity TTM | -193.31% |
Revenue TTM | 184.5M |
Revenue Per Share TTM | 1.63 |
Quarterly Revenue Growth YOY | 481.79999999999995% |
Gross Profit TTM | 69.8M |
EBITDA | -610.9M |
Diluted Eps TTM | -5.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.73 |
EPS Estimate Next Year | -2.59 |
EPS Estimate Current Quarter | -1.32 |
EPS Estimate Next Quarter | -1.3 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 80.13%
Technicals Summary
Sell
Neutral
Buy
Apellis Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Apellis Pharmaceuticals Inc | -9.66% | -50.11% | -35.63% | 17.95% | 138.87% |
 Moderna, Inc. | -5.74% | -34.14% | -17.98% | 43.27% | 454.19% |
 Regeneron Pharmaceuticals, Inc. | -1.77% | -1.68% | 9.3% | 33.59% | 106.18% |
 Novo Nordisk A/s | -7.65% | 10.71% | 66.6% | 150.37% | 305.83% |
 Seagen, Inc. | 2.57% | 3.72% | 52.7% | 4.95% | 167.21% |
 Vertex Pharmaceuticals Incorporated | -0.89% | 9.77% | 14.81% | 28.32% | 82.99% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | NA | NA | NA | -4.73 | -1.93 | -0.4 | 0.0 | 2.94 |
Moderna, Inc. | 34.44 | 34.44 | 0.0 | -3.45 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.94 | 21.94 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 43.71 | 43.71 | 2.03 | 1.66 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 27.05 | 27.05 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Apellis Pharmaceuticals Inc | Buy | $4.5B | 138.87% | NA | 0.0% |
Moderna, Inc. | Buy | $39.3B | 454.19% | 34.44 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $88.8B | 106.18% | 21.94 | 33.93% |
Novo Nordisk A/s | Buy | $411.7B | 305.83% | 43.71 | 33.4% |
Seagen, Inc. | Hold | $39.7B | 167.21% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $89.1B | 82.99% | 27.05 | 35.4% |
Institutional Holdings
venBio Select Advisor LLC
9.44%Vanguard Group Inc
7.99%T. Rowe Price Associates, Inc.
6.01%Wellington Management Company LLP
5.66%BlackRock Inc
4.88%T. Rowe Price Investment Management,Inc.
4.79%
Corporate Announcements
Apellis Pharmaceuticals Inc Earnings
Apellis Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Organization | Apellis Pharmaceuticals Inc |
Employees | 767 |
CEO | Dr. Cedric Francois M.D., Ph.D. |
Industry | Distribution Services |
Discover More
Dropbox, Inc.
$37.55
-3.56%
Dlocal Limited
$37.55
-3.56%
Brazil Capped Etf Msci Ishares
$37.55
-3.56%
Boston Properties Inc.
$37.55
-3.56%
Industrials Vanguard
$37.55
-3.56%
Silver Trust Etf Ishares
$37.55
-3.56%
Pinnacle Financial Partners Inc
$37.55
-3.56%
Berry Plastics Group, Inc.
$37.55
-3.56%
First Horizon Corp.
$37.55
-3.56%